Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.31 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25176756 | 0.96 | MAPK1 (0.33) | GAAALDH1A1MAPK1NPSR1MAPT | |
| SCHEMBL25176681 | 0.90 | ALDH1A1 (0.36) | GAAALDH1A1MAPK1NPSR1MAPT | |
| SCHEMBL20640600 | 0.85 | MAPK1 (0.33) | GAAALDH1A1MAPK1NPSR1MAPT | |
| SCHEMBL25167837 | 0.85 | MAPK1 (0.33) | GAAALDH1A1MAPK1NPSR1MAPT | |
| SCHEMBL20640839 | 0.84 | ALDH1A1 (0.36) | GAAALDH1A1MAPK1NPSR1MAPT | |
| SCHEMBL25174186 | 0.81 | MAPK1 (0.33) | GAAALDH1A1MAPK1NPSR1MAPT | |
| SCHEMBL20640606 | 0.80 | — | — | |
| SCHEMBL20640710 | 0.79 | MAPK1 (0.33) | GAAALDH1A1MAPK1NPSR1MAPT | |
| SCHEMBL26695907 | 0.78 | ALDH1A1 (0.36) | GAAALDH1A1MAPK1NPSR1MAPT | |
| SCHEMBL30712123 | 0.78 | MAPT (0.39) | GAAMAPK1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118251397-A | LRRK2 inhibitors | H.隆德贝克有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11993612-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2024-05-28 | — | — | US | disclosed |
| CN-117425660-A | Aromatic heterocyclic compound, intermediate thereof, pharmaceutical composition and application | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230416272-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-12-28 | — | — | US | disclosed |
| WO-2023222005-A1 | AROMATIC HETEROCYCLIC COMPOUND AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-11-23 | — | — | WO | disclosed |
| US-11780851-B2 | LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| WO-2023073013-A9 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-08-17 | — | — | WO | disclosed |
| US-20230144725-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20230144725-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| WO-2023073013-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-04 | — | — | WO | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| EP-3652179-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-05-20 | — | — | EP | disclosed |
| CN-110891954-A | Inhibitors of leucine-rich repeat kinase 2 | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993612-B2 | LRRK2 inhibitors | LRRK2, PARK7, PINK1 | GAA 90/4885ALDH1A1 2464/4885MAPK1 148/4885 |
| US-11780851-B2 | LRRK2 inhibitors | LRRK2, PARK7, PINK1 | GAA 90/4885ALDH1A1 2464/4885MAPK1 148/4885 |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | LRRK2, PARK7, PINK1 | GAA 438/4885ALDH1A1 4577/4885MAPK1 232/4885 |
| US-20230416272-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | GAA 90/4885ALDH1A1 2464/4885MAPK1 148/4885 |
| US-20230144725-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | GAA 90/4885ALDH1A1 2464/4885MAPK1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.